JP2001512748A5 - - Google Patents

Download PDF

Info

Publication number
JP2001512748A5
JP2001512748A5 JP2000506324A JP2000506324A JP2001512748A5 JP 2001512748 A5 JP2001512748 A5 JP 2001512748A5 JP 2000506324 A JP2000506324 A JP 2000506324A JP 2000506324 A JP2000506324 A JP 2000506324A JP 2001512748 A5 JP2001512748 A5 JP 2001512748A5
Authority
JP
Japan
Prior art keywords
influenza
antigen
cell
vaccine
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000506324A
Other languages
English (en)
Japanese (ja)
Other versions
JP5132851B2 (ja
JP2001512748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1998/005106 external-priority patent/WO1999007839A2/en
Publication of JP2001512748A publication Critical patent/JP2001512748A/ja
Publication of JP2001512748A5 publication Critical patent/JP2001512748A5/ja
Application granted granted Critical
Publication of JP5132851B2 publication Critical patent/JP5132851B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000506324A 1997-08-05 1998-08-05 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用 Expired - Lifetime JP5132851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97202434.3 1997-08-05
EP97202434 1997-08-05
PCT/EP1998/005106 WO1999007839A2 (en) 1997-08-05 1998-08-05 Immunoprotective influenza antigen and its use in vaccination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009239092A Division JP2010059164A (ja) 1997-08-05 2009-10-16 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用

Publications (3)

Publication Number Publication Date
JP2001512748A JP2001512748A (ja) 2001-08-28
JP2001512748A5 true JP2001512748A5 (https=) 2006-01-12
JP5132851B2 JP5132851B2 (ja) 2013-01-30

Family

ID=8228624

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000506324A Expired - Lifetime JP5132851B2 (ja) 1997-08-05 1998-08-05 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用
JP2009239092A Pending JP2010059164A (ja) 1997-08-05 2009-10-16 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009239092A Pending JP2010059164A (ja) 1997-08-05 2009-10-16 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用

Country Status (10)

Country Link
US (1) US7732130B2 (https=)
EP (1) EP0996717B1 (https=)
JP (2) JP5132851B2 (https=)
AT (1) ATE312172T1 (https=)
AU (1) AU745951B2 (https=)
CA (1) CA2297786C (https=)
DE (1) DE69832706T2 (https=)
DK (1) DK0996717T3 (https=)
ES (1) ES2255181T3 (https=)
WO (1) WO1999007839A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
HK1052949B (en) * 2000-04-14 2011-04-29 Wisconsin Alumni Research Foundation Viruses comprising mutated ion channel protein
WO2001083528A2 (en) * 2000-05-01 2001-11-08 Powderject Vaccines, Inc. Nucleic acid immunization
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
KR20040111402A (ko) * 2002-03-13 2004-12-31 기린 비루 가부시키가이샤 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
NZ542935A (en) * 2003-04-23 2008-08-29 Wisconsin Alumni Res Found Recombinant influenza viruses holding a mutation in a transmembrane protein gene
CA2530363C (en) * 2003-06-23 2013-05-07 Baxter International Inc. Carrier proteins for vaccines
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
EP1819732A2 (en) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
CA2628837C (en) * 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
WO2007066334A1 (en) 2005-12-06 2007-06-14 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
RU2009105099A (ru) 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
KR20090096414A (ko) 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 재조합 리노바이러스 벡터
DK2069503T3 (da) * 2006-11-15 2016-02-15 Folia Biotech Inc Papayamosaikvirus-baserede vacciner mod influenza
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EP2173376B1 (en) 2007-08-02 2015-03-25 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
EP2217064A4 (en) * 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
CA2742288A1 (en) * 2008-07-30 2010-02-04 Folia Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
CN102549152B (zh) * 2009-07-31 2015-11-25 帕克斯瓦克斯股份有限公司 基于腺病毒的载体
CN102612559B (zh) 2009-08-28 2015-06-10 一般财团法人化学及血清疗法研究所 源自流感m2的修饰的肽疫苗
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
WO2011054995A2 (es) 2009-11-06 2011-05-12 Chimera Pharma, S. L. U. VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CA3014435C (en) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Improved influenza b virus replication for vaccine development
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919044A (en) 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
WO1992022575A1 (en) * 1991-06-19 1992-12-23 Sri International M-protein peptides of influenza virus as antiviral agents
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
AU687805B2 (en) * 1993-04-27 1998-03-05 United Biomedical Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ATE215124T1 (de) * 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
JP4484969B2 (ja) 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US20020015951A1 (en) 2000-01-06 2002-02-07 Bader Joel S. Method of analyzing a nucleic acid

Similar Documents

Publication Publication Date Title
JP2001512748A5 (https=)
CA2297786A1 (en) New immunoprotective influenza antigen and its use in vaccination
US11938221B2 (en) Multivalent nanoparticle-based vaccines
JP7465310B2 (ja) 多用途性且つ効率的な遺伝子発現のためのrnaレプリコン
JP7788787B2 (ja) 遺伝子発現増強のための組成物および方法
Moser et al. Virosomal adjuvanted antigen delivery systems
Arnold et al. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit
EP2204187A1 (en) Human flu vaccine containing four influenza peptides
US20090304735A1 (en) Immunogenic Compositions
EA012037B1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
Plotkin Six revolutions in vaccinology
US11352416B2 (en) Mosaic chimeric viral vaccine particle
Neurath et al. Viral structural components as immunogens of prophylactic value
US5882650A (en) Cross-reactive influenza A immunization
CN118750594B (zh) 一种二价猪口蹄疫mRNA疫苗及其制备方法和应用
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
Yang et al. Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection
Wu et al. Nanovaccines to combat virus‐related diseases
Skrastina et al. Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein
Beauverger et al. Measles virus hemagglutinin induces an Ld-restricted CD8+ cytotoxic T lymphocyte response to two specific epitopes
JPWO2021051153A5 (https=)
CA2090005C (en) Cross-reactive influenza a immunization
Cogan Towards new vaccines against virus infection:(European Molecular Biology Organization Workshop) 20–23 June 1983, Espoo, Finland
JPWO1995007099A1 (ja) ワクチンおよびその製造方法
pertussis Novavax et al. Covid-19 Vaccines: Several technologies at work